Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Title: Can changing the physical environment promote walking and cycling? A systematic review of what works and how.

Panter J, Guell C, Humphreys D, Ogilvie D.

Health Place. 2019 Jul 10;58:102161. doi: 10.1016/j.healthplace.2019.102161. [Epub ahead of print] Review.

PMID:
31301599
2.

Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer.

Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR.

Cancer Res. 2019 Jul 4. pii: canres.3645.2018. doi: 10.1158/0008-5472.CAN-18-3645. [Epub ahead of print]

PMID:
31273064
3.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

4.

Driving status, travel modes and accelerometer-assessed physical activity in younger, middle-aged and older adults: a prospective study of 90 810 UK Biobank participants.

Hajna S, White T, Panter J, Brage S, Wijndaele K, Woodcock J, Ogilvie D, Imamura F, Griffin SJ.

Int J Epidemiol. 2019 Apr 19. pii: dyz065. doi: 10.1093/ije/dyz065. [Epub ahead of print]

PMID:
31004155
5.

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.

Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.

Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.

6.

Fluoromethylcyclopropylamine derivatives as potential in vivo toxicophores - A cautionary disclosure.

Acton B, Small HF, Smith KM, McGonagle A, Stowell AIJ, James DI, Hamilton NM, Hamilton N, Hitchin JR, Hutton CP, Waddell ID, Ogilvie DJ, Jordan AM.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):560-562. doi: 10.1016/j.bmcl.2018.12.066. Epub 2019 Jan 2.

7.

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.

Waszkowycz B, Smith KM, McGonagle AE, Jordan AM, Acton B, Fairweather EE, Griffiths LA, Hamilton NM, Hamilton NS, Hitchin JR, Hutton CP, James DI, Jones CD, Jones S, Mould DP, Small HF, Stowell AIJ, Tucker JA, Waddell ID, Ogilvie DJ.

J Med Chem. 2018 Dec 13;61(23):10767-10792. doi: 10.1021/acs.jmedchem.8b01407. Epub 2018 Nov 19.

PMID:
30403352
8.

Characteristics of the environment and physical activity in midlife: Findings from UK Biobank.

Smith L, Panter J, Ogilvie D.

Prev Med. 2019 Jan;118:150-158. doi: 10.1016/j.ypmed.2018.10.024. Epub 2018 Oct 25.

9.

Changes in workplace car parking and commute mode: a natural experimental study.

Knott CS, Sharp SJ, Mytton OT, Ogilvie D, Panter J.

J Epidemiol Community Health. 2019 Jan;73(1):42-49. doi: 10.1136/jech-2018-210983. Epub 2018 Oct 3.

10.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

11.

Using alternatives to the car and risk of all-cause, cardiovascular and cancer mortality.

Panter J, Mytton O, Sharp S, Brage S, Cummins S, Laverty AA, Wijndaele K, Ogilvie D.

Heart. 2018 Nov;104(21):1749-1755. doi: 10.1136/heartjnl-2017-312699. Epub 2018 May 21.

12.

Longitudinal association between change in the neighbourhood built environment and the wellbeing of local residents in deprived areas: an observational study.

Foley L, Coombes E, Hayman D, Humphreys D, Jones A, Mitchell R, Ogilvie D.

BMC Public Health. 2018 Apr 24;18(1):545. doi: 10.1186/s12889-018-5459-9.

13.

Towards co-designing active ageing strategies: A qualitative study to develop a meaningful physical activity typology for later life.

Guell C, Panter J, Griffin S, Ogilvie D.

Health Expect. 2018 Oct;21(5):919-926. doi: 10.1111/hex.12686. Epub 2018 Apr 6.

14.

Changes in the mode of travel to work and the severity of depressive symptoms: a longitudinal analysis of UK Biobank.

Knott CS, Panter J, Foley L, Ogilvie D.

Prev Med. 2018 Jul;112:61-69. doi: 10.1016/j.ypmed.2018.03.018. Epub 2018 Mar 28.

15.

Patterns of health behaviour associated with active travel: a compositional data analysis.

Foley L, Dumuid D, Atkin AJ, Olds T, Ogilvie D.

Int J Behav Nutr Phys Act. 2018 Mar 21;15(1):26. doi: 10.1186/s12966-018-0662-8.

16.

Experiences of connectivity and severance in the wake of a new motorway: Implications for health and well-being.

Nimegeer A, Thomson H, Foley L, Hilton S, Crawford F, Ogilvie D; M74 study team.

Soc Sci Med. 2018 Jan;197:78-86. doi: 10.1016/j.socscimed.2017.11.049. Epub 2017 Nov 29.

17.

Physical activity and the environment: conceptual review and framework for intervention research.

Panter J, Guell C, Prins R, Ogilvie D.

Int J Behav Nutr Phys Act. 2017 Nov 15;14(1):156. doi: 10.1186/s12966-017-0610-z. Review.

18.

Does exposure to new transport infrastructure result in modal shifts? Patterns of change in commute mode choices in a four-year quasi-experimental cohort study.

Heinen E, Harshfield A, Panter J, Mackett R, Ogilvie D.

J Transp Health. 2017 Sep;6:396-410. doi: 10.1016/j.jth.2017.07.009.

19.

Associations of active commuting with body fat and visceral adipose tissue: A cross-sectional population based study in the UK.

Mytton OT, Ogilvie D, Griffin S, Brage S, Wareham N, Panter J.

Prev Med. 2018 Jan;106:86-93. doi: 10.1016/j.ypmed.2017.10.017. Epub 2017 Oct 10.

20.

Population levels of, and inequalities in, active travel: A national, cross-sectional study of adults in Scotland.

Olsen JR, Mitchell R, Mutrie N, Foley L, Ogilvie D; M74 study.

Prev Med Rep. 2017 Sep 28;8:129-134. doi: 10.1016/j.pmedr.2017.09.008. eCollection 2017 Dec.

21.

Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.

Mould DP, Bremberg U, Jordan AM, Geitmann M, McGonagle AE, Somervaille TCP, Spencer GJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4755-4759. doi: 10.1016/j.bmcl.2017.08.052. Epub 2017 Aug 24.

PMID:
28927796
22.

Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.

Mould DP, Alli C, Bremberg U, Cartic S, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Somervaille TCP, Spencer GJ, Turlais F, Ogilvie D.

J Med Chem. 2017 Oct 12;60(19):7984-7999. doi: 10.1021/acs.jmedchem.7b00462. Epub 2017 Sep 21.

PMID:
28892629
23.

Effect of a new motorway on social-spatial patterning of road traffic accidents: A retrospective longitudinal natural experimental study.

Olsen JR, Mitchell R, Ogilvie D; M74 study team.

PLoS One. 2017 Sep 7;12(9):e0184047. doi: 10.1371/journal.pone.0184047. eCollection 2017.

24.

Effects of urban motorways on physical activity and sedentary behaviour in local residents: a natural experimental study.

Prins RG, Foley L, Mutrie N, Ogilvie DB; M74 study team.

Int J Behav Nutr Phys Act. 2017 Jul 27;14(1):102. doi: 10.1186/s12966-017-0557-0.

25.

Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.

Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small HF, Somervaille TCP, Ogilvie D.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3190-3195. doi: 10.1016/j.bmcl.2017.05.018. Epub 2017 May 8.

PMID:
28545974
26.

Health impacts of the M74 urban motorway extension: a mixed-method natural experimental study.

Ogilvie D, Foley L, Nimegeer A, Olsen JR, Mitchell R, Thomson H, Crawford F, Prins R, Hilton S, Jones A, Humphreys D, Sahlqvist S, Mutrie N.

Southampton (UK): NIHR Journals Library; 2017 Apr.

27.

Questioning the application of risk of bias tools in appraising evidence from natural experimental studies: critical reflections on Benton et al., IJBNPA 2016.

Humphreys DK, Panter J, Ogilvie D.

Int J Behav Nutr Phys Act. 2017 Apr 19;14(1):49. doi: 10.1186/s12966-017-0500-4.

28.

Effects of living near an urban motorway on the wellbeing of local residents in deprived areas: Natural experimental study.

Foley L, Prins R, Crawford F, Humphreys D, Mitchell R, Sahlqvist S, Thomson H, Ogilvie D; M74 study team.

PLoS One. 2017 Apr 5;12(4):e0174882. doi: 10.1371/journal.pone.0174882. eCollection 2017.

29.

Can environmental improvement change the population distribution of walking?

Panter J, Ogilvie D; iConnect consortium.

J Epidemiol Community Health. 2017 Jun;71(6):528-535. doi: 10.1136/jech-2016-208417. Epub 2017 Mar 7.

30.

The modelled impact of increases in physical activity: the effect of both increased survival and reduced incidence of disease.

Mytton OT, Tainio M, Ogilvie D, Panter J, Cobiac L, Woodcock J.

Eur J Epidemiol. 2017 Mar;32(3):235-250. doi: 10.1007/s10654-017-0235-1. Epub 2017 Mar 3.

31.

New walking and cycling infrastructure and modal shift in the UK: A quasi-experimental panel study.

Song Y, Preston J, Ogilvie D; iConnect consortium.

Transp Res Part A Policy Pract. 2017 Jan;95:320-333. doi: 10.1016/j.tra.2016.11.017.

32.

Negotiating multisectoral evidence: a qualitative study of knowledge exchange at the intersection of transport and public health.

Guell C, Mackett R, Ogilvie D.

BMC Public Health. 2017 Jan 5;17(1):17. doi: 10.1186/s12889-016-3940-x.

33.

Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.

Jones S, Ahmet J, Ayton K, Ball M, Cockerill M, Fairweather E, Hamilton N, Harper P, Hitchin J, Jordan A, Levy C, Lopez R, McKenzie E, Packer M, Plant D, Simpson I, Simpson P, Sinclair I, Somervaille TC, Small H, Spencer GJ, Thomson G, Tonge M, Waddell I, Walsh J, Waszkowycz B, Wigglesworth M, Wiseman DH, Ogilvie D.

J Med Chem. 2016 Dec 22;59(24):11120-11137. Epub 2016 Dec 5.

PMID:
28002956
34.

Effects of living near a new urban motorway on the travel behaviour of local residents in deprived areas: Evidence from a natural experimental study.

Foley L, Prins R, Crawford F, Sahlqvist S, Ogilvie D; M74 study team.

Health Place. 2017 Jan;43:57-65. doi: 10.1016/j.healthplace.2016.11.008. Epub 2016 Nov 26.

35.

An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells.

James DI, Durant S, Eckersley K, Fairweather E, Griffiths LA, Hamilton N, Kelly P, O'Connor M, Shea K, Waddell ID, Ogilvie DJ.

Version 2. F1000Res. 2016 Apr 25 [revised 2016 Jan 1];5:736. eCollection 2016.

36.

IncucyteDRC: An R package for the dose response analysis of live cell imaging data.

Chapman PJ, James DI, Watson AJ, Hopkins GV, Waddell ID, Ogilvie DJ.

F1000Res. 2016 May 23;5:962. eCollection 2016.

37.

First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib.

James DI, Smith KM, Jordan AM, Fairweather EE, Griffiths LA, Hamilton NS, Hitchin JR, Hutton CP, Jones S, Kelly P, McGonagle AE, Small H, Stowell AI, Tucker J, Waddell ID, Waszkowycz B, Ogilvie DJ.

ACS Chem Biol. 2016 Nov 18;11(11):3179-3190. Epub 2016 Oct 12.

PMID:
27689388
38.

Associations between access to recreational physical activity facilities and body mass index in Scottish adults.

Ellaway A, Lamb KE, Ferguson NS, Ogilvie D.

BMC Public Health. 2016 Aug 9;16:756. doi: 10.1186/s12889-016-3444-8.

39.

Scaling up physical activity interventions worldwide: stepping up to larger and smarter approaches to get people moving.

Reis RS, Salvo D, Ogilvie D, Lambert EV, Goenka S, Brownson RC; Lancet Physical Activity Series 2 Executive Committee.

Lancet. 2016 Sep 24;388(10051):1337-48. doi: 10.1016/S0140-6736(16)30728-0. Epub 2016 Jul 28. Review.

40.

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.

Watson AJ, Hopkins GV, Hitchin S, Begum H, Jones S, Jordan A, Holt S, March HN, Newton R, Small H, Stowell A, Waddell ID, Waszkowycz B, Ogilvie DJ.

Version 2. F1000Res. 2016 May 26 [revised 2016 Jan 1];5:1005. doi: 10.12688/f1000research.8724.2. eCollection 2016.

41.

Cycling and Diabetes Prevention: Practice-Based Evidence for Public Health Action.

Panter J, Ogilvie D.

PLoS Med. 2016 Jul 12;13(7):e1002077. doi: 10.1371/journal.pmed.1002077. eCollection 2016 Jul.

42.

Effects of new motorway infrastructure on active travel in the local population: a retrospective repeat cross-sectional study in Glasgow, Scotland.

Olsen JR, Mitchell R, Ogilvie D; M74 study team.

Int J Behav Nutr Phys Act. 2016 Jul 7;13:77. doi: 10.1186/s12966-016-0403-9.

43.

Longitudinal associations of active commuting with body mass index.

Mytton OT, Panter J, Ogilvie D.

Prev Med. 2016 Sep;90:1-7. doi: 10.1016/j.ypmed.2016.06.014. Epub 2016 Jun 13.

44.

Effects of new urban motorway infrastructure on road traffic accidents in the local area: a retrospective longitudinal study in Scotland.

Olsen JR, Mitchell R, Mackay DF, Humphreys DK, Ogilvie D; M74 study team.

J Epidemiol Community Health. 2016 Nov;70(11):1088-1095. doi: 10.1136/jech-2016-207378. Epub 2016 Jun 8.

46.

Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.

Hornyak P, Askwith T, Walker S, Komulainen E, Paradowski M, Pennicott LE, Bartlett EJ, Brissett NC, Raoof A, Watson M, Jordan AM, Ogilvie DJ, Ward SE, Atack JR, Pearl LH, Caldecott KW, Oliver AW.

Biochem J. 2016 Jul 1;473(13):1869-79. doi: 10.1042/BCJ20160180. Epub 2016 Apr 20.

47.

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, Small HF, Vishwanath S, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2724-9. doi: 10.1016/j.bmcl.2016.03.100. Epub 2016 Mar 30.

48.

Changing the environment to improve population health: a framework for considering exposure in natural experimental studies.

Humphreys DK, Panter J, Sahlqvist S, Goodman A, Ogilvie D.

J Epidemiol Community Health. 2016 Sep;70(9):941-6. doi: 10.1136/jech-2015-206381. Epub 2016 Apr 7.

49.

A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.

Stowell AI, James DI, Waddell ID, Bennett N, Truman C, Hardern IM, Ogilvie DJ.

Anal Biochem. 2016 Jun 15;503:58-64. doi: 10.1016/j.ab.2016.03.016. Epub 2016 Mar 29.

PMID:
27036617
50.

Qualitative research can inform clinical practice.

Panter J, Guell C, Ogilvie D.

BMJ. 2016 Mar 15;352:i1482. doi: 10.1136/bmj.i1482. No abstract available.

PMID:
26980313

Supplemental Content

Loading ...
Support Center